logo-loader
viewMedlab Clinical Ltd

Medlab Clinical accelerating VMS business in Australia, and NanaBis globally

Medlab Clinical Ltd (ASX:MDC) managing director & CEO Sean Hall catches up with Proactive Investors about the biotech's progress so far in 2019.

Hall teases, "We're planning on having around about 3000 pharmacies utilising the Medlab VMS range before this calendar year is out."

Progress is also being made with the NanoCelle drug delivery platform. Clinical and human trials are ongoing for NanaBis and NanoStat. On the back of this, Medlab has been making strong moves into Europe.

Quick facts: Medlab Clinical Ltd

Price: 0.365 AUD

ASX:MDC
Market: ASX
Market Cap: $78.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medlab Clinical forges ahead in new vitamin trials for chronic illnesses

Medlab Clinical Ltd (ASX:MDC) chief executive officer Sean Hall tells Proactive Investors how the company is tapping into new areas of its “therapeutic toolkit” to better assist those with chronic health conditions.   Hall says there has been a shortfall in the standard of...

on 05/07/2019

2 min read